SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

OSX Osteopore Limited

Healthcare · Medical Instruments & Supplies · website
$0.00
52wk 0.00 – 0.03
Overall
38.6
Value
99.6
Growth
71.4
Health
0.0
Quality
0.0
Momentum
3.7
Dividend
—
Price
About Osteopore Limited

Osteopore Limited, a regenerative medicine company, engages in the production of 3D-printed biomimetic and bioresorbable implants in Vietnam, South Korea, the Philippines, Singapore, India, Taiwan, Indonesia, the Netherlands, the United Arab Emirates, Australia, and internationally. The company commercializes products designed to enable natural bone healing across multiple therapeutic areas. Its technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. It manufactures and trades medical implants and medical devices; and provides technology services, as well as engages in research and experimental development on biotechnology and medical science. Osteopore Limited was founded in 2003 and is headquartered in Singapore.

Price analytics

Returns

1 day 33.3%
1 week 0.0%
1 month -20.0%
3 months -20.0%
6 months -42.9%
1 year -63.6%
3 years -99.5%

Risk

Volatility (1y ann.) 192.3%
Beta vs ASX 200 -0.20
Sharpe (1y) 0.35
VaR 95% (1-day) -18.2%
Max drawdown (1y) -88.5%
Off 1-year high -84.6%

Technicals

RSI(14) 50
vs 50DMA -7.2%
vs 200DMA -38.9%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 99.6
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
98
Growth 71.4
Revenue growth (1y)
43
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 0.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
0
Debt / Equity
—
Quality (Profitability & Cash Flow) 0.0
Return on equity
—
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 3.7
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
14
Position in 52-week range
4

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$2.77M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
-0.02
EV / EBITDA
-1.31
Price / Book
-1.33
ROE
—
Operating margin
-115.5%
Net margin
-135.8%
Total cash
$1.28M
Total debt
$2.78M
Current ratio
0.61
Debt / Equity
—
Free cash flow
$-2.50M
Avg volume
1.11M
Latest annual results (FY ending 31 Dec 2025)
  • Revenue$3.06M
  • Gross profit$2.37M
  • Operating income-$3.41M
  • Net income-$3.72M
  • Diluted EPS—
  • Free cash flow-$2.55M
  • Net debt$2.14M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4